? Cancer Control Program The Cancer Control Program (CCP) is a highly collaborative and transdisciplinary Program that focuses on identifying and analyzing the genetic, behavioral, and health care determinants of cancer susceptibility and outcomes in diverse and vulnerable populations and on developing, evaluating and implementing interventions to lower risk and improve cancer outcomes. CCP is one of two Population Science Research Programs of the Abramson Cancer Center (ACC). CCP has 39 members who work intra- and inter-Programmatically to apply advances in science to population health and cutting-edge data analytics, address the cancer burdens and risk factors in our catchment area, and train the next generation of cancer control researchers. Members conduct research within four broad and interconnected Program aims: 1) Cancer Genomics and Risk; 2) Communication and Health Behavior; 3) Cancer Survivorship; and 4) Health Care Outcomes. CCP has produced a substantial body of high impact work in the current funding period. In Cancer Genomics and Risk, members have established the basis for clinical management of individuals with moderate penetrance risk genes for breast and colorectal cancer, identified risk loci associated with susceptibility to testicular germ cell tumors, and established the comparable efficacy of genetic counseling delivered through telehealth. In Communication and Health Behavior, members have conducted innovative studies on the use of incentives for improving early detection and novel transdisciplinary research in diet, obesity and cancer. In Cancer Survivorship, members have established clinical paradigms for cancer survivors through patient-centered care plans and have revealed important complexities in end of life care. In Health Outcomes, members have innovated methods to use the electronic health record to improve health behaviors and have conducted pragmatic trials to innovate new models of high-quality cancer care. CCP recruited 17 new members during the current funding period in the areas of epidemiology, genomics, biostatistics, informatics, nutrition and the microbiome. CCP works closely with the Tobacco and Environmental Carcinogenesis Program to create a robust population science presence at the ACC. CCP members come from ten departments in the Perelman School of Medicine, School of Nursing, Wharton School of Business, and Annenberg School for Communication. There have been 640 cancer-related publications over the current funding period (13% intra- Programmatic, 35% inter-Programmatic, 76% multi-institutional). Members have 30 R01-equivalents, $14.5M (direct) in annual cancer-related research funding, of which $11.6M is peer-reviewed and $3.8M is from NCI. During the funding period, CCP members enrolled 10,768 subjects onto interventional trials (with 819 onto treatment trials) and 2,923 subjects onto non-interventional trials. In sum, CCP is a vibrant community of interactive population science investigators working across four inter-connected aims to further research impacting our catchment area and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088749
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Bengsch, Bertram; Ohtani, Takuya; Khan, Omar et al. (2018) Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. Immunity 48:1029-1045.e5
Nair, Praful R; Alvey, Cory; Jin, Xiaoling et al. (2018) Filomicelles Deliver a Chemo-Differentiation Combination of Paclitaxel and Retinoic Acid That Durably Represses Carcinomas in Liver to Prolong Survival. Bioconjug Chem 29:914-927
Bhagwat, Neha; Dulmage, Keely; Pletcher Jr, Charles H et al. (2018) An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. Sci Rep 8:5035
Raposo-Ferreira, Talita M M; Brisson, Becky K; Durham, Amy C et al. (2018) Characteristics of the Epithelial-Mesenchymal Transition in Primary and Paired Metastatic Canine Mammary Carcinomas. Vet Pathol 55:622-633
Kasner, Margaret T; Mick, Rosemarie; Jeschke, Grace R et al. (2018) Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. Invest New Drugs 36:657-666
Karakasheva, Tatiana A; Lin, Eric W; Tang, Qiaosi et al. (2018) IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res 78:4957-4970
Huffman, Austin P; Richman, Lee P; Crisalli, Lisa et al. (2018) Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 24:594-599
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32

Showing the most recent 10 out of 1047 publications